Sentinel node identification using technetium-99m neomannosyl human serum albumin in esophageal cancer

Hyun Koo Kim, Seungeun Kim, Jong Jae Park, Jae Min Jeong, Young Jae Mok, Young Ho Choi

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Background: This study is a clinical trial designed to test the reliability and feasibility of sentinel node detection using a new mannose receptor radioactive binding agent in patients with esophageal squamous cell carcinoma. Methods: Twenty-three patients (21 men, 2 women; mean age 61.0±8.60 years) who were candidates for esophagectomy with conventional lymph node dissection for thoracic esophageal cancer were enrolled. A total dose of 1mCi of 99mTc-MSA [technetium-99m neomannosyl human serum albumin] in 0.2 mL was administered at 4 quadrants into the submucosal layer around the primary tumor under esophagoscopic guidance approximately 1 hour before surgery. Intraoperative sentinel node sampling was subsequently followed by esophagectomy. All harvested lymph nodes were cut into 2-mm slices and ultimately diagnosed using formalin-fixed and paraffin-embedded sections with hematoxylin and eosin staining. Results: The number of dissected lymph nodes per patient was 30.5 ± 9.18 (1547). Among 23 patients, the sentinel lymph nodes could be identified in 21 patients (91.3%). The sentinel nodes could be identified in all 21 patients with cT1 or T2N0M0 (100%) disease; these patients were candidates for sentinel lymph node navigation surgery for the esophageal cancer. The mean number of sentinel nodes identified was 2.6 ± 1.35 (range, 15) per patient. No false-negative sentinel lymph nodes were detected in any of the 8 patients with node-positive disease (0%). Conclusions: Intraoperative sentinel lymph node identification using 99mTc-MSA was feasible and reliable in patients with esophageal squamous cell carcinoma.

Original languageEnglish
Pages (from-to)1517-1522
Number of pages6
JournalAnnals of Thoracic Surgery
Volume91
Issue number5
DOIs
Publication statusPublished - 2011 May 1

Fingerprint

Technetium
Esophageal Neoplasms
Serum Albumin
Esophagectomy
Lymph Nodes
cyhalothrin
Proxy
Hematoxylin
Eosine Yellowish-(YS)
Lymph Node Excision
Paraffin
Formaldehyde
Thorax
Clinical Trials
Staining and Labeling
Sentinel Lymph Node

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery
  • Pulmonary and Respiratory Medicine

Cite this

Sentinel node identification using technetium-99m neomannosyl human serum albumin in esophageal cancer. / Kim, Hyun Koo ; Kim, Seungeun; Park, Jong Jae; Jeong, Jae Min; Mok, Young Jae; Choi, Young Ho.

In: Annals of Thoracic Surgery, Vol. 91, No. 5, 01.05.2011, p. 1517-1522.

Research output: Contribution to journalArticle

Kim, Hyun Koo ; Kim, Seungeun ; Park, Jong Jae ; Jeong, Jae Min ; Mok, Young Jae ; Choi, Young Ho. / Sentinel node identification using technetium-99m neomannosyl human serum albumin in esophageal cancer. In: Annals of Thoracic Surgery. 2011 ; Vol. 91, No. 5. pp. 1517-1522.
@article{dbbd11cc87bd4ccda847928bacbf3ceb,
title = "Sentinel node identification using technetium-99m neomannosyl human serum albumin in esophageal cancer",
abstract = "Background: This study is a clinical trial designed to test the reliability and feasibility of sentinel node detection using a new mannose receptor radioactive binding agent in patients with esophageal squamous cell carcinoma. Methods: Twenty-three patients (21 men, 2 women; mean age 61.0±8.60 years) who were candidates for esophagectomy with conventional lymph node dissection for thoracic esophageal cancer were enrolled. A total dose of 1mCi of 99mTc-MSA [technetium-99m neomannosyl human serum albumin] in 0.2 mL was administered at 4 quadrants into the submucosal layer around the primary tumor under esophagoscopic guidance approximately 1 hour before surgery. Intraoperative sentinel node sampling was subsequently followed by esophagectomy. All harvested lymph nodes were cut into 2-mm slices and ultimately diagnosed using formalin-fixed and paraffin-embedded sections with hematoxylin and eosin staining. Results: The number of dissected lymph nodes per patient was 30.5 ± 9.18 (1547). Among 23 patients, the sentinel lymph nodes could be identified in 21 patients (91.3{\%}). The sentinel nodes could be identified in all 21 patients with cT1 or T2N0M0 (100{\%}) disease; these patients were candidates for sentinel lymph node navigation surgery for the esophageal cancer. The mean number of sentinel nodes identified was 2.6 ± 1.35 (range, 15) per patient. No false-negative sentinel lymph nodes were detected in any of the 8 patients with node-positive disease (0{\%}). Conclusions: Intraoperative sentinel lymph node identification using 99mTc-MSA was feasible and reliable in patients with esophageal squamous cell carcinoma.",
author = "Kim, {Hyun Koo} and Seungeun Kim and Park, {Jong Jae} and Jeong, {Jae Min} and Mok, {Young Jae} and Choi, {Young Ho}",
year = "2011",
month = "5",
day = "1",
doi = "10.1016/j.athoracsur.2011.01.016",
language = "English",
volume = "91",
pages = "1517--1522",
journal = "Annals of Thoracic Surgery",
issn = "0003-4975",
publisher = "Elsevier USA",
number = "5",

}

TY - JOUR

T1 - Sentinel node identification using technetium-99m neomannosyl human serum albumin in esophageal cancer

AU - Kim, Hyun Koo

AU - Kim, Seungeun

AU - Park, Jong Jae

AU - Jeong, Jae Min

AU - Mok, Young Jae

AU - Choi, Young Ho

PY - 2011/5/1

Y1 - 2011/5/1

N2 - Background: This study is a clinical trial designed to test the reliability and feasibility of sentinel node detection using a new mannose receptor radioactive binding agent in patients with esophageal squamous cell carcinoma. Methods: Twenty-three patients (21 men, 2 women; mean age 61.0±8.60 years) who were candidates for esophagectomy with conventional lymph node dissection for thoracic esophageal cancer were enrolled. A total dose of 1mCi of 99mTc-MSA [technetium-99m neomannosyl human serum albumin] in 0.2 mL was administered at 4 quadrants into the submucosal layer around the primary tumor under esophagoscopic guidance approximately 1 hour before surgery. Intraoperative sentinel node sampling was subsequently followed by esophagectomy. All harvested lymph nodes were cut into 2-mm slices and ultimately diagnosed using formalin-fixed and paraffin-embedded sections with hematoxylin and eosin staining. Results: The number of dissected lymph nodes per patient was 30.5 ± 9.18 (1547). Among 23 patients, the sentinel lymph nodes could be identified in 21 patients (91.3%). The sentinel nodes could be identified in all 21 patients with cT1 or T2N0M0 (100%) disease; these patients were candidates for sentinel lymph node navigation surgery for the esophageal cancer. The mean number of sentinel nodes identified was 2.6 ± 1.35 (range, 15) per patient. No false-negative sentinel lymph nodes were detected in any of the 8 patients with node-positive disease (0%). Conclusions: Intraoperative sentinel lymph node identification using 99mTc-MSA was feasible and reliable in patients with esophageal squamous cell carcinoma.

AB - Background: This study is a clinical trial designed to test the reliability and feasibility of sentinel node detection using a new mannose receptor radioactive binding agent in patients with esophageal squamous cell carcinoma. Methods: Twenty-three patients (21 men, 2 women; mean age 61.0±8.60 years) who were candidates for esophagectomy with conventional lymph node dissection for thoracic esophageal cancer were enrolled. A total dose of 1mCi of 99mTc-MSA [technetium-99m neomannosyl human serum albumin] in 0.2 mL was administered at 4 quadrants into the submucosal layer around the primary tumor under esophagoscopic guidance approximately 1 hour before surgery. Intraoperative sentinel node sampling was subsequently followed by esophagectomy. All harvested lymph nodes were cut into 2-mm slices and ultimately diagnosed using formalin-fixed and paraffin-embedded sections with hematoxylin and eosin staining. Results: The number of dissected lymph nodes per patient was 30.5 ± 9.18 (1547). Among 23 patients, the sentinel lymph nodes could be identified in 21 patients (91.3%). The sentinel nodes could be identified in all 21 patients with cT1 or T2N0M0 (100%) disease; these patients were candidates for sentinel lymph node navigation surgery for the esophageal cancer. The mean number of sentinel nodes identified was 2.6 ± 1.35 (range, 15) per patient. No false-negative sentinel lymph nodes were detected in any of the 8 patients with node-positive disease (0%). Conclusions: Intraoperative sentinel lymph node identification using 99mTc-MSA was feasible and reliable in patients with esophageal squamous cell carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=79955394002&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955394002&partnerID=8YFLogxK

U2 - 10.1016/j.athoracsur.2011.01.016

DO - 10.1016/j.athoracsur.2011.01.016

M3 - Article

VL - 91

SP - 1517

EP - 1522

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

SN - 0003-4975

IS - 5

ER -